Marché du diagnostic de la leucémie lymphoïde aiguë (LLA) au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et perspectives du marché du diagnostic de la leucémie lymphoïde aiguë/lymphoblastique (LAL) au Moyen-Orient et en Afrique

Le cancer du sang est le cancer le plus répandu dans le monde depuis plusieurs décennies. Les taux d'incidence du cancer sont en hausse tant chez les hommes que chez les femmes. Il survient légèrement plus fréquemment chez les hommes que chez les femmes. La leucémie lymphoïde aiguë (LLA) représente environ deux pour cent des néoplasmes lymphoïdes aux États-Unis. Les patients présentent généralement des symptômes liés à l'anémie, à la thrombocytopénie et à la neutropénie en raison du remplacement de la moelle osseuse par la tumeur. La forte concurrence dans les thérapies diagnostiques de la leucémie et le besoin d'améliorer les diagnostics dans le monde entier ont augmenté la demande de divers services dans ce secteur. Diverses entreprises ont lancé de nombreux produits de diagnostic pour répondre à la demande mondiale croissante du marché du diagnostic de la leucémie lymphoïde/lymphoblastique aiguë (LLA) au Moyen-Orient et en Afrique.

Cependant, le coût élevé du traitement du cancer de la leucémie, y compris les thérapies, les médicaments et autres, est l'un des facteurs les plus importants. En conséquence, la croissance du marché peut être entravée à long terme. Le coût des produits de diagnostic est l'un des éléments qui peuvent poser problème aux fournisseurs d'appareils de diagnostic de la leucémie.

Data Bridge Market Research analyse que le marché du diagnostic de la leucémie lymphoïde aiguë/lymphoblastique (LAL) au Moyen-Orient et en Afrique devrait atteindre la valeur de 74,98 millions USD d'ici 2030, à un TCAC de 5,7 % au cours de la période de prévision. Le type de produit représente le segment le plus important du marché en raison de la demande rapide de diagnostics de la leucémie en Afrique du Sud. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.

Market Definition

Acute lymphocytic leukemia (ALL) is a malignancy of B or T-lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to the replacement of bone marrow elements and other lymphoid organs resulting in a characteristic disease pattern. B-cells are a specific type of lymph cell that affect a body's immune system. Two types of B-cell leukemia are prolymphocytic leukemia (PLL) and Hairy Cell Leukemia (HCL). Symptoms include fatigue, easy or spontaneous bruising and bleeding, and infections. Additionally, B-symptoms, such as fever, night sweats, and unintentional weight loss, are often present but may be mild, and hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central Nervous System (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure. T-cell lymphoblastic leukemia is most common among children aged over five years. The increasing cases of cancer worldwide and the rising prevalence of lymphoblastic leukemia are expected to drive segmental T-cell acute lymphoblastic leukemia market growth. These white blood cell acutely influences white platelets called T- lymphocytes. The Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is expected to show significant growth due to the rising prevalence of T-cell acute lymphoblastic leukemia, research and development activities, and high healthcare expenditure.

Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Growing prevalence of leukemia cancer

All ages can be affected by leukemia. Leukemia can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Acute lymphoblastic leukemia has the highest emergency presenting rates of any cancer kind, with a leukemia emergency diagnostic rate of 37% on average.

The most frequent form of juvenile cancer is acute lymphoblastic leukemia, a heterogeneous illness defined by unchecked lymphoid progenitor proliferation that typically begins in utero. Although the prevalence of ALL has been rising significantly in recent decades, there is still no apparent cause for this development. Rising maternal obesity rates may be partially responsible for the rise in ALL prevalence.

Thus, acute leukemia incidence has been rising Middle East and Africa due to various risk factors, becoming a significant socio-economic issue. This is expected to act as a driver in the Middle East and Africa acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.

•  Novel technological advancements in leukemia diagnostics

The most common form of blood cancer, acute lymphoblastic leukemia (ALL), is also one of the main causes of death. The blood is invaded by this form of cancer, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis.

The risk of prescribing the incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the leukemia disease's devastating effects. Multiple segmentation techniques constituted the foundation of the existing leukemia classification algorithms.

The manual examination of stained blood smear microscopy pictures used in current practice for the initial diagnosis of ALL is time-consuming and prone to error. A potent tool for aiding doctors in making medical decisions has emerged: deep learning-based human-centric biomedical diagnostics. Various computer-aided diagnostic techniques have been created to recognize ALL blood pictures automatically.

The development of several new diagnostic methods will increase the market's growth as many new and advanced products are launched. Hence, it is expected to create demand for acute leukemic cancer diagnosis in the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Restraint

• Late diagnosis and poor prognosis of leukemia

Cancer is the leading cause of death Middle East and Africaly. By 2030, it is anticipated that there will be 13.1 million more cancer-related deaths per year. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potentially cancerous signs, patient delays may result. The main cause of delayed presentation is thought to be a lack of public knowledge of early cancer signs, especially if such symptoms are unusual.

The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the Middle East and Africa acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.

Opportunities

• Increase in diagnostic products for leukemia

A blood-forming tissue cancer impairs the body's capability to combat infection. Bone marrow is one of the blood-forming tissues that can develop leukemia. Numerous varieties include chronic lymphocytic leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Many patients with leukemia that grow slowly do not exhibit any symptoms. Fatigue, weight loss, recurrent infections, and easy bruising or bleeding are all possible symptoms of leukemia that grow quickly. Treatment results vary greatly. Treatment for leukemia with a slow growth rate may involve monitoring. Chemotherapy for malignant leukemia is occasionally combined with radiation therapy and stem cell transplant.

Thus, the rise in diagnostic product approvals has led to an increased number of highly efficient products in the market for leukemia diagnosis treatment. This is expected to create an opportunity for the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

• Government initiatives toward cancer diagnostics

The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease worldwide. Leukemia has increased very rapidly in individuals in past decades. Leukemia is the most prevalent cancer, with 60,650 new cases in 2022, according to cancer.gov.

There are several initiatives taken by the government that helps boost the market's demand, and these initiatives will increase awareness among people regarding their health and take early diagnosis for better cure and precaution. For this reason, government initiatives towards cancer diagnostics are acting as an opportunity for growing the demand of the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Challenge

• Increased cost, safety, and convenience issue

Leukemia is fatal cancer, and the diagnosis process of leukemia also has safety issues; it is not cost-effective. One of the most costly medical disorders to treat Middle East and Africaly is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.

Rising helium shortage and rising risk of excessive radiation exposure are projected to restrict the use of CT scanners, threatening the possibilities of rising capital investments and low benefit-cost ratio for biomarkers. Many hospitals in developing countries cannot invest in diagnostic imaging equipment, which has led to an increase in the use of reconstructed diagnostic imaging due to high expenditures and financial restrictions. Due to the increasing demand for diagnostic imaging operations in these nations, hospitals that can't afford to buy new, cutting-edge imaging systems instead choose to employ refurbished imaging equipment, which could have long-term negative effects.

Henceforth, the current leukemia diagnosis process has safety, cost, and convenience issues, which are expected to challenge the growth of the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Post-COVID-19 Impact on Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market

The cancer diagnostics market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics have greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.

Manufacturers make various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results in the cancer diagnostics market.

Recent Developments

• In October 2022, Thermo Fisher Scientific Inc. announced that it had entered into a definitive agreement to acquire The Binding Site Group, a Middle East and Africa leader in specialty diagnostics. The acquisition will help in the development of the specialty diagnostics segment.
• In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System. This next-generation digital PCR system helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases.

Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Scope

The Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into product type, test type, cancer type, age group, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Product Type

• Instruments
• Consumables & Accessories

On the basis of product type, the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into instruments, consumables & accessories.

Test Type

• Imaging Test
• Biopsy
• Blood Test
• Others

On the basis of test type, the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into imaging test, biopsy, blood test, and others.

Cancer Type

•  B-cell Lymphoblastic Leukemia /Lymphoma
• T-cell Lymphoblastic Leukemia

On the basis of cancer type, the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into B-cell lymphoblastic leukemia/lymphoma and T-cell lymphoblastic leukemia.

By Age Group

• Below 21
• 21-29
• 30-65
• 65 and Above

On the basis of age group, the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into below 21, 21-29, 30-65, 65 and above.

By Gender

• Male
• Female

On the basis of gender, the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into male and female.

By End User

• Hospital
• Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

On the basis of end user, the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

By Distribution Channel

• Direct Tender
• Retail Sales

On the basis of distribution channel, the Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into direct tender and retail sales.

Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Regional Analysis/Insights

The Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is analyzed, and market size information is provided by country, product type, test type, cancer type, age group, gender, end user, and distribution channel.

Some countries covered in this Middle East and Africa acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market report are South Africa, Saudi Arabia, the UAE, Egypt, Israel, and the rest of the Middle East and Africa.

L'Afrique du Sud devrait dominer en raison de la présence d'acteurs clés du marché sur le plus grand marché de consommation avec un PIB élevé et devrait croître en raison de nouvelles avancées technologiques dans le diagnostic de la leucémie au Moyen-Orient et en Afrique sur le marché du diagnostic de la leucémie aiguë lymphocytaire/lymphoblastique (LAL).

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements de réglementation nationale qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique et les défis rencontrés en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse de la concurrence et des parts de marché des diagnostics de la leucémie lymphoïde aiguë/lymphoblastique (LAL) au Moyen-Orient et en Afrique

Le paysage concurrentiel du marché des diagnostics de la leucémie lymphoïde/lymphoblastique aiguë (LAL) au Moyen-Orient et en Afrique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications et la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché des diagnostics de la leucémie lymphoïde/lymphoblastique aiguë (LAL) au Moyen-Orient et en Afrique.

Français Certains des principaux acteurs opérant sur le marché du diagnostic de la leucémie aiguë lymphoblastique (LAL) au Moyen-Orient et en Afrique sont F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN, Abbott, Merck KGaA, Hologic, Inc., Agilent Technologies, Inc., DiaSorin SpA, Illumina, Inc., BIOMÉRIEUX, Myriad Genetics, Inc., Quest Diagnostics Incorporated., Bio-Rad Laboratories, Inc., Koninklijke Philips NV, BD, MinFound Medical Systems Co., Ltd entre autres.

SKU-69604